H Krum

Summary

Affiliation: Monash University
Country: Australia

Publications

  1. von Lueder T, Wang B, Kompa A, Huang L, Webb R, Jordaan P, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015;8:71-8 pubmed publisher
    ..This may be contributed to by superior inhibition of LCZ696 on cardiac fibrosis and cardiac hypertrophy than either stand-alone neprilysin inhibitor or angiotensin receptor blocker. ..
  2. Krum H, Skiba M, Gilbert R. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Diabet Med. 2003;20:708-12 pubmed
    ..5 mg/day. ..
  3. Krum H, Lambert E, Windebank E, Campbell D, Esler M. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. Am J Physiol Heart Circ Physiol. 2006;290:H1706-12 pubmed
    ..We conclude that sympathetic nervous inhibition is not a major component of the blood pressure-lowering action of ARBs in essential hypertension. ..
  4. Krum H, Swergold G, Curtis S, Kaur A, Wang H, Smugar S, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009;27:886-93 pubmed publisher
    ..Treatment with etoricoxib vs. diclofenac was also a significant factor for increased BP. CCBs appear to maintain antihypertensive effects with concurrent NSAID therapy better than other examined antihypertensive drug classes. ..
  5. Krum H, Massie B, Abraham W, Dickstein K, Kober L, McMurray J, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (. Eur J Heart Fail. 2011;13:107-14 pubmed publisher
    ..Perspective The ATMOSPHERE study will definitively determine the role of a DRI strategy additional to or as an alternative to conventional RAAS blockade in patients with chronic systolic HF. ..